A Phase II Study Evaluating the Safety, Efficacy, and Intracranial Activity of Tarlatamab in Recurrent/Refractory Gliomas With IDH Mutation (TARGID)
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Tarlatamab (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- Acronyms TARGID
- 17 Jan 2025 New trial record